Document:

EX-4.17

 Exhibit 4.17 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE
SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

MANNKIND CORPORATION 

WARRANT TO PURCHASE COMMON STOCK 

Warrant No.: 2015-[    ] 

Issuance Date: November 16, 2015 
 Expiration Date:
November 16, 2020 
 THIS CERTIFIES THAT, for value received,
[                                    ] or its assigns
(the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from MANNKIND CORPORATION, a Delaware corporation (the
“Company”), up to [            ] shares of the Company’s Common Stock (the “Common Stock”). 

This Warrant is being issued pursuant to the terms of the Investment Banking Agreement, dated October 5, 2015, by and between the Company
and Sunrise Securities Corp. 
 1. DEFINITIONS. As used herein, the following terms shall have the following
respective meanings: 
 (a) “Exercise Period” means the period commencing with the date hereof and ending five
(5) years later, unless sooner terminated as provided below. 
 (b) “Exercise Price” means $2.61 (USD)
per share, subject to adjustment pursuant to Section 5 below. 
 (c) “Exercise Shares” means the shares
of Common Stock issuable upon exercise of this Warrant, subject to adjustment pursuant to the terms herein, including but not limited to adjustment pursuant to Section 5 below. 

(d) “Securities Act” means the Securities Act of 1933, as amended. 

(e) “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a
trust, an unincorporated organization, any other entity and a government or any department or agency thereof. 
 (f)
“Trading Day” means any day on which the Common Stock is traded on The NASDAQ Global Market, or, if The NASDAQ Global Market is not the principal trading market for the Common Stock, then on the principal securities
exchange or securities market on which the Common Stock is then traded; provided that “Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any
day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour
ending at 4:00:00 p.m., New York Time). 

  
 1 

 2. EXERCISE OF WARRANT. 

2.1 Mechanics of Exercise. This Warrant may be exercised in whole or in part at any time during the Exercise Period by delivery of the
following to the Company at its address set forth on the signature page hereto (or at such other address as it may designate by notice in writing to the Holder): (a) a duly executed and completed Notice of Exercise in the form attached hereto;
and (b) if the Holder is not electing a Cashless Exercise (as defined below) to the extent permitted pursuant to Section 2.2 below, payment to the Company of an amount equal to the Exercise Price multiplied by the number of Exercise Shares
as to which this Warrant is being exercised (the “Aggregate Exercise Price”) in cash, by check or wire transfer of immediately available funds to an account designated by the Company (a “Cash
Exercise”). All payments hereunder shall be made in U.S. Dollars. The Holder shall not be required to surrender this Warrant in order to effect an exercise hereunder, provided that in the event of an exercise of this Warrant for all
Exercise Shares then issuable hereunder, this Warrant is surrendered to the Company by the second (2nd) Trading Day (as defined below) following the date on which the Company has received each of (i) the Notice of Exercise and, if this
Warrant is being exercised pursuant to a Cash Exercise, the Aggregate Exercise Price (collectively, the “Exercise Delivery Documents”). On or before the first (1st) Trading Day following the date on which the Company has
received the Exercise Delivery Documents, the Company shall transmit by email or facsimile an acknowledgment of confirmation of receipt of the Exercise Delivery Documents to the Holder and the Company’s transfer agent for the Common Stock (the
“Transfer Agent”). The Company shall deliver any objection to the Exercise Delivery Documents on or before the first (1st) Trading Day following the date on which the Company has received all of the Exercise Delivery
Documents. In the event of any discrepancy or dispute, the records of the Company shall be controlling and determinative in the absence of manifest error. On or before the third (3rd) Trading Day following the date on which the Company has
received the Exercise Delivery Documents (the “Share Delivery Date”), the Company shall, upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such
exercise to the Holder’s or its designee’s balance account with The Depository Trust Company (“DTC”) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast
Automated Securities Transfer Program (the “FAST Program”) or if the certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in
the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. Upon delivery of the
Exercise Delivery Documents, the Holder shall be deemed for all purposes to have become the holder of record of the Exercise Shares with respect to which this Warrant has been exercised, irrespective of the date such Exercise Shares are credited to
the Holder’s DTC account or the date of delivery of the certificates evidencing such Exercise Shares, as the case may be. If this Warrant is submitted to the Company in connection with an exercise and the number of Exercise Shares represented
by this Warrant submitted for exercise is greater than the number of Exercise Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than five (5) Trading Days after any exercise and at its
own expense, issue a new Warrant representing the right to purchase the number of Exercise Shares purchasable immediately prior to such exercise under this Warrant, less the number of Exercise Shares with respect to which this Warrant is exercised.
The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Exercise Shares upon exercise hereof. 

2.2 Cashless Exercise. Notwithstanding anything contained herein to the contrary, if (i) a registration statement registering for
resale the Exercise Shares under the Securities Act is not effective or available for the Exercise Shares and (ii) an exemption from registration under the Securities Act for resale of the Exercise Shares is not available for the Exercise
Shares, then the Holder may, in its sole discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment 

  
 2 

 
otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares of
Common Stock determined according to the following formula (a “Cashless Exercise”): 
  

			
	 Net Number = (A x B) - (A x C)

B

	
	For purposes of the foregoing formula:
		
	A=	  	the total number of Exercise Shares with respect to which this Warrant is then being exercised.
		
	B=	  	the Weighted Average Price (as defined below) of the shares of Common Stock (as reported by Bloomberg (as defined below)) on the date immediately preceding the date of the Exercise Notice.
		
	C=	  	the Exercise Price then in effect for the applicable Exercise Shares at the time of such exercise.

 For purposes of the above calculation, “Weighted Average Price” means, for any
security as of any date, the dollar volume-weighted average price for such security on The NASDAQ Global Market during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg
Financial Markets (“Bloomberg”) through its “Volume at Price” function; or, if the foregoing does not apply, the volume-weighted average price of such security on the Tel Aviv Stock Exchange
(“TASE”) in U.S. Dollars (based on the exchange rate between the New Israeli Shekel and the U.S. Dollar on such day) during the period beginning at 8:30:01 a.m., Israel Time, and ending at 4:30:00 p.m., Israel time as
reported by Bloomberg, or, if no volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price in U.S. Dollars (based on the exchange rate
between the New Israeli Shekel and the U.S. Dollar on such day) of any of the market makers for such security as reported by any reliable financial reporting medium; or if the foregoing doesn’t apply, in the over-the-counter market on the
electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for
such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the “pink sheets” by Pink OTC Markets Inc. If the
Weighted Average Price cannot be calculated for such security on such date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder.
All such determinations shall be appropriately adjusted for any share dividend, share split or other similar transaction during such period. 

2.3 Limitations on Exercise. The Company shall not effect the exercise of this Warrant, and the Holder shall not have the right to
exercise this Warrant, to the extent that after giving effect to such exercise, such Holder (together with such Holder’s affiliates and any other Persons acting as a group together) would beneficially own in excess of 4.99% (the
“Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by
the Holder and its affiliates shall include the number of shares of Common Stock issuable upon exercise of this 

  
 3 

 
Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise of the remaining,
unexercised portion of this Warrant beneficially owned by the Holder and its affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by the Holder and its
affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding
sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), it being acknowledged that the
Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act, and the Holder is solely responsible for any schedules required to be filed in accordance therewith. For purposes of this
Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Form 10-K, Proxy Statement, Form 10-Q, Current
Report on Form 8-K or other public filing with the Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding. For any reason at any time, upon the written or oral request of the Holder, where such request indicates that it is being made pursuant to this Warrant, the Company shall within one (1) Trading Day
confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of
the Company, including the Warrant, by the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may increase or decrease the Maximum
Percentage to any other percentage not in excess of 9.99% specified in such notice; provided, that any such increase will not be effective until the 61st day after such notice is delivered to the Company. 

3. COVENANTS OF THE COMPANY. 

3.1 Covenants to Register Exercise Shares. The Company covenants and agrees, within 30 days from the date hereof or such later time as
may be agreed upon by Sunrise Securities Corp. and the Company, to register for resale the Exercise Shares pursuant to a prospectus supplement under the Company’s Registration Statement on Form S-3 (Registration No. 333-206778), subject to
Holder’s timely delivery to the Company of any information reasonably requested by the Company in connection with such registration. The Holder acknowledges that the Company has no obligation to register this Warrant. The Holder agrees to
indemnify and holder harmless the Company and each of its directors and officers from and against any losses, claims, damages or liabilities (joint or several) to which the Company or any of its directors or officers may become subject under the
Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any of the following statements: (i) any untrue statement or
alleged untrue statement of a material fact contained in such prospectus supplement or incorporated by reference therein or in any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact
required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act (each, a “Holder Violation”), in each case to
the extent (and only to the extent) that such Holder Violation occurs in reliance upon and in conformity with written information furnished by the Holder to the Company or its attorneys and stated to be specifically for use in connection with such
registration; and the Holder will reimburse any legal or other expenses reasonably incurred by the Company or any of its director or officer in connection with investigating or defending any such loss, claim, damage, liability or action if it is
judicially determined that there was such a Holder Violation. 

  
 4 

 3.2 Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise
Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance
thereof. The Company further covenants and agrees that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of shares of its Common Stock to provide for the exercise
of the rights represented by this Warrant. 
 4. REPRESENTATIONS OF HOLDER. 

4.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that it is acquiring this Warrant and the Exercise
Shares solely for its account for investment and not with a present view toward the public distribution of this Warrant or Exercise Shares or any part thereof and has no present intention of selling or distributing this Warrant or Exercise Shares or
any arrangement or understanding with any other persons regarding the sale or distribution of this Warrant or the Exercise Shares. The Holder will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any
offers to buy, purchase or otherwise acquire or take a pledge of) this Warrant or the Exercise Shares in violation of any applicable law or regulation, including, without limitation: the Securities Act and the rules and regulations thereunder; the
Exchange Act and the rules and regulations thereunder; the rules and regulations of the Financial Industry Regulatory Authority (“FINRA”), including, if applicable, FINRA Rule 5110(g); and the rules and regulations of The
NASDAQ Global Market or the Tel Aviv Stock Exchange, as applicable. The Holder represents and warrants that (i) it is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company
to reach an informed and knowledgeable decision regarding its investment in this Warrant and, upon exercise of this Warrant, any Exercise Shares and (ii) it is experienced in making investments of this type and has such knowledge and background
in financial and business matters that the Holder is capable of evaluating the merits and risks of this investment and protecting the Holder’s own interests. 

4.2 Securities Are Not Registered. 

(a) The Holder understands that this Warrant and the Exercise Shares have not been registered under the Securities Act. 

(b) The Holder recognizes that this Warrant and the Exercise Shares must be held indefinitely unless they are subsequently registered
under the Securities Act or an exemption from such registration is available. 
 (c) The Holder acknowledges and agrees that the
Securities are “restricted securities” as defined in Rule 144 promulgated under the Securities Act as in effect from time to time and must be held indefinitely unless they are subsequently registered under the Securities Act or an
exemption from such registration is available. The Holder has been advised or is aware of the provisions of Rule 144, which permits limited resale of securities purchased in a private placement subject to the satisfaction of certain conditions,
including, among other things: the availability of certain current public information about the Company, the resale occurring following the required holding period under Rule 144 and the number of securities being sold during any three-month period
not exceeding specified limitations. 

  
 5 

 4.3 Disposition of Warrant and Exercise Shares. 

(a) The Holder further agrees not to make any disposition of all or any part of this Warrant or Exercise Shares in any event unless
and until: 
 (i) There is then in effect a registration statement under the Securities Act covering such proposed disposition and
such disposition is made in accordance with said registration statement; or 
 (ii) The Holder shall have notified the Company of
the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished the Company with an
opinion of counsel, reasonably satisfactory to the Company, for the Holder to the effect that such disposition will not require registration of such Warrant or Exercise Shares under the Securities Act or any applicable state securities laws. 

(b) The Holder understands and agrees that all certificates evidencing the shares to be issued to the Holder may bear the following
legend prior to being registered under the Securities Act: 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED. 
 4.4 Accredited Investor Status. The Holder is an “accredited investor” as such term is
defined in Rule 501 under the Securities Act. 
 4.5 Further Assurances. The Holder agrees and covenants that at any time and from
time to time it will promptly execute and deliver to the Company such further instruments and documents and take such further action as the Company may reasonably require in order to carry out the full intent and purpose of this Warrant and to
comply with state or federal securities laws or other regulatory approvals. 
 5. ADJUSTMENT OF
EXERCISE PRICE. In the event of changes in the outstanding Common Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations,
reorganizations, liquidations, or the like, the number and class of shares available under this Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of this Warrant, on exercise for the same aggregate
Exercise Price, the total number, class, and kind of shares as the Holder would have owned had this Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment; provided,
however, that such adjustment shall not be made with respect to, and this Warrant shall terminate if not exercised prior to, the events set forth in Section 7 below. The form of this Warrant need not be changed because of any adjustment in the
number of Exercise Shares subject to this Warrant. Notwithstanding anything to the contrary in this Warrant, in no event shall the Exercise Price be reduced below the par value of the Company’s Common Stock. 

6. FRACTIONAL SHARES. No fractional shares shall be issued upon the exercise of this Warrant as a
consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of any fractional share.
If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting
from multiplying the then current closing price of the Common Stock on the principal securities exchange on which the Common Stock is listed by such fraction. 

  
 6 

 7. EARLY TERMINATION. In the event of, at any time during
the Exercise Period, (i) any consolidation or merger of the Company with or into another Person, (ii) the transfer of all or substantially all of the assets of the Company to another Person or (iii) the consummation of a stock
purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of
Common Stock of the Company, then the Company shall provide to the Holder five (5) days’ advance written notice of such transaction (which notice shall be deemed given in the event the Company makes a broadly accessible public announcement
of such transaction), and this Warrant shall terminate unless exercised prior to the closing of such transaction. 
 8. NO
STOCKHOLDER RIGHTS. This Warrant in and of itself shall not entitle the Holder to any voting rights, any rights to receive notices required to be given to the Company’s stockholders, any rights to receive any
dividend or other distribution of assets, or any other rights as a stockholder of the Company. 
 9. TRANSFER
OF WARRANT. During the Exercise Period and prior to the full exercise of this Warrant for all Exercise Shares, Holder may, subject to compliance with all applicable laws and regulations and the transfer restrictions
set forth herein, transfer this Warrant and all rights hereunder by surrendering this Warrant to the Company or its Transfer Agent, as directed by the Company, together with all applicable transfer taxes, whereupon the Company will, or will cause
its Transfer Agent to, forthwith issue and deliver upon the order of the Holder a new Warrant registered in the name of the transferee designated by Holder, representing the right to purchase the number of Exercise Shares being transferred by the
Holder and, if less than the total number of Exercise Shares then underlying this Warrant is being transferred, a new Warrant) to the Holder representing the right to purchase the number of Exercise Shares not being transferred. The acceptance of
the new Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the new Warrant that the Holder has in respect of this Warrant. 

10. LOST, STOLEN, MUTILATED OR DESTROYED WARRANT.
If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new
Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or
destroyed Warrant shall be at any time enforceable by anyone. 
 11. NOTICES, ETC. All notices required
or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed email or facsimile if sent during normal business hours of the recipient,
if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a internationally recognized
overnight courier, specifying next day delivery, with written verification of delivery. All communications shall be sent to the party to be notified at the address listed below such party’s signature on the signature page hereto, or at such
other address as the party may designate by ten (10) days’ advance written notice to the other party hereto. 
 12.
ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. 

  
 7 

 13. GOVERNING LAW. This Warrant and all rights, obligations
and liabilities hereunder shall be governed by the laws of the State of New York, without regard to conflict of laws principles that would cause the application of laws of any other jurisdiction. 

[SIGNATURE PAGE FOLLOWS] 

  
 8 

 IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its duly authorized officer as of the Issuance Date set forth on the first page of this Warrant. 
  

			
	COMPANY:
	
	MANNKIND CORPORATION
		
	By:	 	 
	Name:	 	Matthew J. Pfeffer
	Title:	 	Corporate Vice President and Chief Financial Officer
		
	Address: 	 	 25134 Rye Canyon Loop, Suite 300
 Valencia,
California 91355
 Attn: Rose Alinaya

  

			
	HOLDER:
	
	[                            ]
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
		
	Address:	 	 

  
 9 

 NOTICE OF EXERCISE 

TO: MANNKIND CORPORATION 

(1)  ̈ Cash Exercise. The undersigned hereby elects to purchase
                         shares of the Common Stock of MANNKIND
CORPORATION, a Delaware corporation (the “Company”), pursuant to the Cash Exercise terms of the attached Warrant (the “Warrant”), and tenders herewith payment of the
Aggregate Exercise Price in full, together with all applicable transfer taxes, if any. 
  ̈
Cashless Exercise. The undersigned hereby elects to purchase                          shares of the Common Stock of
the Company pursuant to the Cashless Exercise terms of the Warrant, and shall tender payment of all applicable transfer taxes, if any. 

(2) Delivery of Exercise Shares. The Company shall deliver to the Holder
                         Exercise Shares in accordance with the terms of the Warrant. 

(3) The undersigned represents that (i) unless the aforesaid shares have been registered for resale under the Securities Act of
1933, as amended (the “Securities Act”), the aforesaid shares are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that
the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach
an informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned
is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own interests; (iv) unless the aforesaid shares have been registered for resale under an effective registration statement, prospectus and
prospectus supplement filed with the Securities and Exchange Commission, the undersigned understands that the shares of Common Stock issuable upon exercise of the Warrant have not been registered under the Securities Act by reason of a specific
exemption from the registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the
Securities Act, they must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) unless the aforesaid shares have been registered for resale under the Securities
Act, the undersigned is aware that the aforesaid shares of Common Stock may not be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met and until the undersigned has held the shares for the period of time
prescribed by Rule 144, that among the conditions for use of Rule 144 is the availability of current information to the public about the Company; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid
shares of Common Stock unless and until there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has
provided the Company with an opinion of counsel satisfactory to the Company, stating that such registration is not required. 

					
			
	   
	 		 	   

	(Date)	 		 	(Signature)
			
		 		 	 
		 		 	 (Print name)

 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute this form and 

supply required information. Do not use this form to 

purchase shares.) 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby
are hereby assigned to 
  

					
	Name:	 	 
		 	(Please Print)
		
	Address: 	 	 
		 	(Please Print)

					
			
	Dated:	 	                    , 20        	  	

					
			
	 Holder’s
 Signature: 
	 	 	  	

					
			
	 Holder’s
 Address: 
	 	 	  	

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant,
without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.EX-10.8

 Exhibit 10.8 
  

			
	

	  	 25134 Rye Canyon Loop

Suite 300
 Valencia, CA 91355

Main: (661) 775-5300
 Fax:
(661) 775-2081
 www.mannkindcorp.com

 March 11, 2016 
 Juergen Martens

 4444 Jardin Street 
 Irving, Texas 75038 

Re: Separation Agreement 
 Dear Juergen: 

This letter sets forth the terms of the separation agreement (the “Agreement”) that MannKind Corporation (the
“Company”) is offering to you to aid in your employment transition. 
 1. Separation. Your employment with
the Company will continue through no later than March 18, 2016, which will become your employment termination date (the “Separation Date”). 

2. Accrued Salary and Paid Time Off. Upon your Separation Date, the Company will pay you all accrued salary, and all accrued and unused
paid time off earned through the Separation Date, subject to standard payroll deductions and withholdings. You will receive these payments regardless of whether you enter into this Agreement. 

3. Severance Benefits. You will be paid the severance benefits described in this Section 4 (the “Severance
Benefits”), provided that, on or within twenty-one (21) days from the Separation Date, you sign, date, and return to the Company, the General Release of Claims (the “General Release”) attached hereto
as Exhibit A, and allow it to become effective in accordance with its terms. The Severance Benefits are as follows: 

(a) Cash Severance Payment. Continuation of your annual base salary as of the Separation Date for a period of twelve (12) months
(the “Severance Period”). 
 (b) COBRA Coverage. If you timely elect continued coverage under the
Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) or any state equivalent, for yourself and your covered dependents under the Company’s group health plans following the Separation Date, then the Company
shall pay the premiums for such health care coverage (such payments, the “COBRA Premiums”) necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the Separation Date until
the earliest of (i) the close of the Severance Period, (ii) the expiration of your eligibility for continuation coverage under COBRA, and (iii) the date when you become eligible for substantially equivalent health insurance coverage
in connection with new employment or self-employment (such period from the termination date through the earliest of (i) through (iii), the “COBRA Payment Period”). If you become eligible for coverage under another
employer’s group health plan or otherwise cease to be eligible for COBRA coverage during the period provided in this section, you must 

 March 11, 2016 

Juergen Martens 
 Page Two 

 

 
immediately notify the Company of such event, and the Company’s obligation to pay COBRA Premiums on your behalf shall cease. In addition, during the COBRA Payment Period, to the extent
permitted under the terms of the applicable plans, the Company will pay for continued additional health coverage (such as Exec-U-Care), life, accidental death and disability and other insurance programs for you and your family members, if
applicable, to the extent such programs existed on the Separation Date (such additional coverage, the “Supplemental Coverage”). Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion,
that its payment of the COBRA Premiums or, as applicable, the premiums for the Supplemental Coverage on your behalf would result in a violation of applicable law (including, without limitation, Section 2716 of the Public Health Service Act),
then in lieu of paying such premiums on your behalf, the Company will pay you on the last day of each remaining month of the COBRA Payment Period a cash payment equal to the amount of such premiums for that month on a post-tax basis, which payment
shall be subject to applicable tax withholding (such amount, the “Special Severance Payment”), such Special Severance Payment to be made without regard to the expiration of the COBRA Payment Period prior to the end of the Severance
Period. Such Special Severance Payment shall end on the earlier of (x) the date on which you commence other employment and (y) the close of the Severance Period. 

(c) Equity Acceleration. The vesting of each of your time-based RSUs and Options will be accelerated such that you will become vested
in those RSUs and Options that would have vested during the Severance Period had you remained an employee of the Company through such date. Please note that your vested Option shares will be exercisable pursuant to the terms of the Plans and
applicable grant documents, which typically provide that vested Options may be exercised during a specified period that commences on the Separation Date. 

4. No Other Compensation or Benefits. You acknowledge that, except as expressly provided in this Agreement, you have not earned, you
will not receive and you are not entitled to receive from the Company any additional compensation (including base salary, bonus, or incentive compensation), severance, or benefits prior to, on, or after the Separation Date, including, but not
limited to the Executive Severance Agreement between you and the Company dated October 10, 2007. For clarity, if all other Senior Executives employed by the Company do not receive an annual bonus for work performed in 2015, you shall not be
entitled to receive such a bonus. In addition, if one or more Senior Executives receives additional equity awards prior to the Separation Date as part of a retention or long-term incentive program, you will not be eligible to receive any such equity
awards. 
 5. Expense Reimbursements. You agree that, within thirty (30) days after the Separation Date, you will submit your
final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement. The Company will reimburse such expenses pursuant to its regular business practice.
If you are required to travel before or during the Transition Period to discharge your duties, then you shall be subject to the same travel expense guidelines as apply to Executive Leadership Team members. 

 March 11, 2016 

Juergen Martens 
 Page Three 

 

 6. Return of Company Property. By the Separation Date, you shall return to the Company
all Company documents (and all copies or reproductions thereof) and other Company property within your possession or control, including, but not limited to, Company hardcopy and electronic files, email, notes, drawings, records, reports, studies,
compilations of data, business plans and forecasts, proposals, agreements, financial and operational information, sales and marketing information, research and development information, product and prototype information, personnel information,
specifications, computer-recorded information, tangible property and equipment including, but not limited to, credit cards, entry cards, identification badges, keys, computing and communication devices; and any materials of any kind that contain or
embody any proprietary or confidential information of the Company (and all reproductions or embodiments thereof, in whole or in part). Your timely return of all such Company documents and other property is a condition precedent to your receipt of
the benefits provided under this Agreement; provided that you are permitted to retain copies of any agreement that you signed with the Company (after leaving with the Company the original or another copy, if you do not possess the original). Your
return of property and information shall include return of a copy of any Company information stored on any personal computing device, and deletion of all such information from your personal devices without retention of any copy or embodiment; and
you agree to permit the Company to inspect any such device, if there is a reasonable basis to suspect that you retained any such documents, to ensure that such return and deletion of information has taken place. 

7. Proprietary Information Protection and Assignment of Rights to Work Product. You acknowledge and agree to abide by your continuing
obligations under your Employee Proprietary Information and Inventions Agreement. You further agree that, both during and after your employment, you will make no use or disclosure of any Company proprietary or confidential information unless
specifically authorized in writing by a Company officer. You hereby assign to the Company all right, title, and interest you may have in any and all inventions, developments, concepts, methods, trade secrets, intellectual property, or other work
product developed or obtained by you during your employment with the Company that relates to any actual or anticipated line of business, product, service, or activity of the Company, or your performance of services for the Company, or was produced
on Company time or equipment. 
 8. Confidentiality. The provisions of this Agreement will be held in strictest confidence by you and
the Company and will not be publicized or disclosed in any manner whatsoever; provided, however, that: (a) you may disclose this Agreement in confidence to your immediate family; (b) the parties may disclose this Agreement in confidence to
their respective attorneys, accountants, auditors, tax preparers, and financial advisors; (c) the Company may disclose this Agreement as necessary to fulfill standard or legally required corporate reporting or disclosure requirements; and
(d) the parties may disclose this Agreement insofar as such disclosure may be necessary to enforce its terms or as otherwise required by law. 

9. Nondisparagement. Both parties agree not to disparage the other party and its officers, directors, employees, shareholders and
agents, in any manner likely to be harmful to them or their business, business reputations or personal reputations, provided that a party may respond accurately and fully to any inquiry to the extent required by legal process. 

 March 11, 2016 

Juergen Martens 
 Page Four 

 

 10. No Admissions. You understand and agree that the promises and payments in
consideration of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person, and that the Company makes no such admission. 

11. Dispute Resolution. To aid in the rapid and economical resolution of any disputes which may arise under this Agreement, you and the
Company agree that any and all claims, disputes or controversies of any nature whatsoever arising from or regarding the interpretation, performance, negotiation, execution, enforcement or breach of this Agreement, your employment, or the termination
of your employment, shall be resolved by confidential, final and binding arbitration conducted before a single arbitrator with JAMS, Inc. (“JAMS”) in the Los Angeles, California area, in accordance with JAMS’ then-applicable
arbitration rules, which appear at the following link: http://www.jamsadr.com/rules-comprehensive-arbitration/. The parties acknowledge that by agreeing to this arbitration procedure, they waive the right to resolve any such dispute through a
trial by jury, judge or administrative proceeding. You will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the
dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as
to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The Company shall bear JAMS’ arbitration fees and administrative costs. Nothing in this Agreement shall prevent
either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and
state courts of any competent jurisdiction. 
 12 Miscellaneous. This Agreement, including all exhibits, constitutes the complete,
final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein,
and it supersedes any other such promises, warranties or representations, including, but not limited to, your employment offer letter, Executive Severance Agreement and Employee Proprietary Information and Inventions Agreement (insofar as it may be
inconsistent with this Agreement). This Agreement may not be modified or amended except in a written agreement signed by both you and a duly authorized officer of the Company. If any provision of this Agreement (including, but not limited to, the
Employee Proprietary Information and Inventions Agreement, incorporated by reference herein) becomes or is declared illegal, unenforceable or void, this Agreement shall continue in full force and effect, and said provision shall be deemed modified
and enforceable consistent with the intent of the parties insofar as possible under applicable law. This Agreement will be construed and enforced in accordance with the laws of the State of California without respect to conflicts of law principles.
Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement must be in writing and shall not be deemed a waiver of any successive breach. This Agreement may be executed in
counterparts and facsimile signatures will suffice as original signatures. 

 March 11, 2016 

Juergen Martens 
 Page Five 

 

 If this Agreement is acceptable to you, please sign below on or within fourteen (14) calendar days and
then promptly return the fully signed original to me. The Company’s offer contained herein will automatically expire if we do not receive the fully signed Agreement from you within this timeframe. 

 March 11, 2016 

Juergen Martens 
 Page Six 

 

 We wish you the best in your future endeavors. 

Sincerely, 
  

			
	MANNKIND CORPORATION
		
	By:	 	/s/ Matthew Pfeffer
		 	 Matthew Pfeffer
 Chief Executive
Officer

 Exhibit A – General Release of Claims 
  

	
	UNDERSTOOD AND AGREED:
	
	/s/ Juergen Martens
	Juergen Martens

			
		
	Date:	 	March 11, 2016

 EXHIBIT A 

SEPARATION DATE RELEASE 

(To be signed on or within 21 days after the Separation Date.) 

In consideration for the various benefits provided to me by MannKind Corporation (the “Company” pursuant to my Separation
Agreement with the Company dated March 11, 2016 (the “Agreement”), I agree to the terms below. 
 I hereby confirm
that: I have been paid all compensation owed for all hours worked by me for the Company; I have received all leave and leave benefits and protections for which I was eligible (pursuant to the Family and Medical Leave Act, the California Family
Rights Act or otherwise) in connection with my work with the Company; and I have not suffered any injury or illness in connection with my work with the Company for which I have not already filed a claim. 

I hereby generally and completely release the Company and its current and former directors, officers, employees, shareholders, partners,
agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any and all claims, liabilities and obligations, both known and unknown, arising from or in any way related to events, acts, conduct,
or omissions occurring prior to and including the time I sign this Separation Date Release (the “Release”). This general release includes, but is not limited to: (1) all claims arising from or in any way related to my
employment with the Company, or the termination of that employment; (2) all claims related to compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, paid time off, expense reimbursements, severance pay,
fringe benefits, stock, stock options, or any other ownership interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (4) all tort claims,
including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees,
or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), ERISA, the
California Fair Employment and Housing Act (as amended), the California Labor Code (as amended), and the California Family Rights Act. 
 I
am not releasing: (i) any rights or claims for indemnification I may have pursuant to any written indemnification agreement with the Company to which I am a party or under applicable law; (ii) any rights which cannot be waived as a matter
of law; (iii) any rights I have to file or pursue a claim for workers’ compensation or unemployment insurance; and (iv) any rights I have pursuant to my Separation Agreement with the Company dated March 11, 2016. In addition,
nothing in this Agreement prevents me from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or any other analogous federal or state government agency, except
that I acknowledge and agree that I hereby waive my right to any monetary benefits in connection with any such claim, charge or proceeding. 

  
 B-1 

 I also acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may
have under the ADEA (“Release ADEA Waiver”). I also acknowledge that the consideration given for the Release ADEA Waiver is in addition to anything of value to which I was already entitled. I further acknowledge that I have been
advised by this writing, as required by the ADEA, that: (a) my release and waiver herein does not apply to any rights or claims that arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this
Release (although I may choose voluntarily not to do so); (c) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily sign it sooner); (d) I have seven (7) days following the date I sign this
Release to revoke it (by sending written revocation directly to the Company’s Chief Executive Officer); and (e) the Release will not be effective until the date upon which the revocation period has expired unexercised, which will be the
eighth day after I sign this Release (the “Release Effective Date”). 
 I UNDERSTAND THAT THIS RELEASE INCLUDES A RELEASE
OF ALL KNOWN AND UNKNOWN CLAIMS. I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to
exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that
section and any law or legal principle of similar effect in any jurisdiction with respect to my release of claims herein, including but not limited to the release of unknown and unsuspected claims. 

This Release, together with the Agreement (including all exhibits thereto), constitutes the complete, final and exclusive embodiment of the
entire agreement between me and the Company with regard to this subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained in the Release or the Agreement, and it
entirely supersedes any other such promises, warranties or representations, whether oral or written. 
  

			
		
	By:	 	 
		 	Juergen Martens

 
			
		
	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]